NCI-H2023 Xenograft Model Overview

The NCI-H2023 xenograft model originates from a human non-small cell lung cancer (NSCLC) adenocarcinoma and serves as a preclinical platform for evaluating therapeutic responses in EGFR wild-type, KRAS wild-type, and TP53-mutant tumor backgrounds. This cell line was derived from the pleural effusion of a male lung cancer patient and is notable for its well-differentiated epithelial morphology, moderate tumorigenic potential, and stable growth kinetics in immunocompromised mice. The NCI-H2023 model is particularly useful for studying therapeutic resistance mechanisms that do not involve classical KRAS or EGFR pathway mutations. It is frequently employed to investigate agents targeting downstream signaling nodes, cell cycle regulators, and apoptotic mediators in a molecularly distinct NSCLC subtype. Given its wild-type RAS/EGFR status and defective p53 signaling, the model reflects a clinically relevant subset of NSCLC that poses therapeutic challenges due to a lack of druggable mutations.

Request a Custom Quote for NCI-H2023 Xenograft Model

Biological and Molecular Characteristics

The NCI-H2023 cell line exhibits a moderately differentiated epithelial phenotype and maintains expression of canonical markers such as cytokeratin 7 and E-cadherin. It is wild-type for both KRAS and EGFR, with loss-of-function mutations in TP53, leading to compromised apoptotic control and genomic instability. The absence of common driver mutations makes this model ideal for evaluating agents that act independently of RAS/EGFR oncogenic activation. Baseline expression of PD-L1 is low to moderate, providing opportunities to test combination strategies that enhance immune recognition. The cell line also expresses functional MHC class I molecules, which is advantageous for studying antigen presentation and T-cell engagement in immunotherapy studies. Moderate expression of BCL-XL and survivin further implicates this model in the exploration of anti-apoptotic pathway inhibition.

Characteristic	Description
Tissue Origin	Human lung (adenocarcinoma, pleural effusion)
Key Genetic Features	KRAS wild-type, EGFR wild-type, TP53 mutant
Cell Morphology	Epithelial, moderately differentiated
Immunomarkers	CK7+, E-cadherin+, PD-L1 (low to moderate)
Pathway Involvement	p53 dysfunction, apoptosis resistance, immune evasion

In Vivo Model Development and Tumorigenicity

The NCI-H2023 xenograft model is established by subcutaneous injection of cultured cells into immunodeficient murine hosts, typically athymic nude or NOD/SCID mice. Tumors are typically detectable within two to three weeks post-inoculation and progress steadily to a size range of 300–500 mm³ over the course of five to six weeks. While its tumorigenicity is moderate compared to more aggressive NSCLC models, the NCI-H2023 line offers controlled growth dynamics and structural consistency across cohorts, making it ideal for experiments requiring precise pharmacokinetic sampling or time-course efficacy studies. The model responds well to repeated dosing protocols and supports the evaluation of pharmacodynamic biomarkers. Due to its epithelial architecture and lack of stromal overgrowth, the xenograft is amenable to histologic and molecular characterization, as well as localized drug delivery studies.

Request a Custom Quote for NCI-H2023 Xenograft Model

Histopathology and Immunohistochemical Profile

Histological assessment of NCI-H2023-derived tumors reveals features consistent with well to moderately differentiated lung adenocarcinoma. Hematoxylin and eosin staining demonstrates cohesive epithelial sheets with glandular differentiation, vesicular nuclei, and moderate mitotic activity. Immunohistochemistry confirms expression of cytokeratin 7 and E-cadherin, validating the epithelial lineage of the xenograft. The Ki-67 proliferation index typically ranges between 40% and 60%, supporting its classification as a moderately proliferative tumor. p53 accumulation is present due to underlying mutation, and PD-L1 expression is variably detectable, though generally limited to subsets of tumor cells. These histologic features support the model’s role in evaluating therapeutic responses in a non-oncogene-addicted NSCLC context, particularly for treatments focused on restoring apoptosis or modulating immune responses.

Preclinical Applications and Drug Response

The NCI-H2023 xenograft model is valuable for testing therapeutics in NSCLC cases lacking canonical oncogenic drivers. Its genetic profile makes it particularly suitable for studying DNA-damaging agents, CDK inhibitors, and BCL-2/BCL-XL antagonists that act through p53-independent mechanisms. It has demonstrated moderate sensitivity to platinum-based chemotherapy and variable response to microtubule-stabilizing agents such as paclitaxel. The model has also been employed in immunotherapy combination studies, where agents that modulate tumor immunogenicity or T-cell infiltration are co-administered with checkpoint inhibitors. Due to its consistent growth and well-differentiated tumor architecture, the model serves as a dependable system for evaluating novel drug delivery platforms, including polymer-based and liposomal formulations, and for conducting pharmacodynamic analyses of tumor-intrinsic resistance mechanisms.

Request This Model

To request the NCI-H2023 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for NCI-H2023 Xenograft Model